<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Cardiovascular Manifestations of COVID-19 | COVID-19 Resources for Penn Cardiologists</title>
  <meta name="description" content="A compliation of COVID-19 resources assembled by cardiology fellows at the Hospital of the University of Pennsylvania" />
  <meta name="generator" content="bookdown 0.18 and GitBook 2.6.7" />

  <meta property="og:title" content="Cardiovascular Manifestations of COVID-19 | COVID-19 Resources for Penn Cardiologists" />
  <meta property="og:type" content="book" />
  
  <meta property="og:image" content="images/SARS-CoV-2_without_background.png" />
  <meta property="og:description" content="A compliation of COVID-19 resources assembled by cardiology fellows at the Hospital of the University of Pennsylvania" />
  <meta name="github-repo" content="mglev1n/PennCVM-COVID" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Cardiovascular Manifestations of COVID-19 | COVID-19 Resources for Penn Cardiologists" />
  
  <meta name="twitter:description" content="A compliation of COVID-19 resources assembled by cardiology fellows at the Hospital of the University of Pennsylvania" />
  <meta name="twitter:image" content="images/SARS-CoV-2_without_background.png" />

<meta name="author" content="Michael Levin, MD; Yoav Karpenshif, MD; Megan Burke, MD; Frank E. Silvestry MD on behalf of the Penn Cardiovascular Fellowship program" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  <link rel="apple-touch-icon-precomposed" sizes="120x120" href="images/SARS-CoV-2_without_background.png" />
  <link rel="shortcut icon" href="images/SARS-CoV-2_without_background.png" type="image/x-icon" />
<link rel="prev" href="index.html"/>
<link rel="next" href="cardiovascular-testing-considerations.html"/>
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<script src="libs/htmlwidgets-1.5.1/htmlwidgets.js"></script>
<script src="libs/d3-3.3.8/d3.min.js"></script>
<script src="libs/dagre-0.4.0/dagre-d3.min.js"></script>
<link href="libs/mermaid-0.3.0/dist/mermaid.css" rel="stylesheet" />
<script src="libs/mermaid-0.3.0/dist/mermaid.slim.min.js"></script>
<link href="libs/DiagrammeR-styles-0.2/styles.css" rel="stylesheet" />
<script src="libs/chromatography-0.1/chromatography.js"></script>
<script src="libs/DiagrammeR-binding-1.0.5.9000/DiagrammeR.js"></script>
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-430TDV0LMW"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-430TDV0LMW');
</script>



</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">COVID-19 Resources for Penn Cardiologists</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html"><i class="fa fa-check"></i>Cardiovascular Manifestations of COVID-19</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#acute-cardiac-injury"><i class="fa fa-check"></i>Acute Cardiac Injury</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#definition"><i class="fa fa-check"></i>Definition</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#pathophysiology"><i class="fa fa-check"></i>Pathophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#prognostic-implications"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#treatment-considerations"><i class="fa fa-check"></i>Treatment Considerations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#acute-coronary-syndrome"><i class="fa fa-check"></i>Acute Coronary Syndrome</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#definition-1"><i class="fa fa-check"></i>Definition</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#pathophysiology-1"><i class="fa fa-check"></i>Pathophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence-1"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics-1"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#treatment-considerations-scai-guidelines"><i class="fa fa-check"></i>Treatment Considerations (SCAI Guidelines)</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#stemi"><i class="fa fa-check"></i>STEMI</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#nstemi"><i class="fa fa-check"></i>NSTEMI</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#arrhythmia"><i class="fa fa-check"></i>Arrhythmia</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence-2"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics-2"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#treatment-considerations-1"><i class="fa fa-check"></i>Treatment Considerations</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#atrial-fibrillationflutter"><i class="fa fa-check"></i>Atrial Fibrillation/Flutter</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#ventricular-tachycardia"><i class="fa fa-check"></i>Ventricular Tachycardia</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#bradyarrhythmia"><i class="fa fa-check"></i>Bradyarrhythmia</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#myopericarditis"><i class="fa fa-check"></i>Myo/Pericarditis</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence-3"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#clinical-presentation"><i class="fa fa-check"></i>Clinical Presentation</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics-3"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#management"><i class="fa fa-check"></i>Management</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#thromboembolic-diseasecoagulopathy"><i class="fa fa-check"></i>Thromboembolic Disease/Coagulopathy</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence-4"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics-4"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#prognostic-implications-1"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#treatment-considerations-2"><i class="fa fa-check"></i>Treatment Considerations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release"><i class="fa fa-check"></i>Secondary Hemophagocytic Lymphohistiocytosis/Cytokine Release</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#definition-2"><i class="fa fa-check"></i>Definition</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#clinical-presentation-1"><i class="fa fa-check"></i>Clinical Presentation</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence-5"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics-5"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#prognostic-implications-2"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#treatment-considerations-3"><i class="fa fa-check"></i>Treatment Considerations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#cardiomyopathyheart-failurecardiogenic-shock"><i class="fa fa-check"></i>Cardiomyopathy/Heart Failure/Cardiogenic Shock</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#incidence-6"><i class="fa fa-check"></i>Incidence</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#diagnostics-6"><i class="fa fa-check"></i>Diagnostics</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#prognostic-implications-3"><i class="fa fa-check"></i>Prognostic Implications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#management-1"><i class="fa fa-check"></i>Management</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#stablechronic"><i class="fa fa-check"></i>Stable/Chronic</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-manifestations-of-covid-19.html"><a href="cardiovascular-manifestations-of-covid-19.html#unstablecardiogenic-shock"><i class="fa fa-check"></i>Unstable/Cardiogenic Shock</a></li>
</ul></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html"><i class="fa fa-check"></i>Cardiovascular Testing Considerations</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry"><i class="fa fa-check"></i>Electrocardiography/Telemetry</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#indications"><i class="fa fa-check"></i>Indications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#recommendations"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#echocardiography"><i class="fa fa-check"></i>Echocardiography</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#indications-1"><i class="fa fa-check"></i>Indications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#special-considerations"><i class="fa fa-check"></i>Special Considerations</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#sample-workflow"><i class="fa fa-check"></i>Sample Workflow</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#cardiac-biomarkers"><i class="fa fa-check"></i>Cardiac Biomarkers</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#indications-2"><i class="fa fa-check"></i>Indications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#recommendations-1"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#coagulation-biomarkers"><i class="fa fa-check"></i>Coagulation Biomarkers</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#indications-3"><i class="fa fa-check"></i>Indications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#recommendations-2"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#inflammatory-biomarkers"><i class="fa fa-check"></i>Inflammatory Biomarkers</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#indications-4"><i class="fa fa-check"></i>Indications</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#recommendations-3"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#deferral-of-non-urgent-testingprocedures"><i class="fa fa-check"></i>Deferral of Non-urgent Testing/Procedures</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#stress-testing-and-imaging"><i class="fa fa-check"></i>Stress Testing and Imaging</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#electrophysiology"><i class="fa fa-check"></i>Electrophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#heart-failuretransplant"><i class="fa fa-check"></i>Heart Failure/Transplant</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#interventional-cardiology"><i class="fa fa-check"></i>Interventional Cardiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#structural-heart-disease"><i class="fa fa-check"></i>Structural Heart Disease</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#cardiac-surgery"><i class="fa fa-check"></i>Cardiac Surgery</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#vascular"><i class="fa fa-check"></i>Vascular</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-testing-considerations.html"><a href="cardiovascular-testing-considerations.html#rehabilitation"><i class="fa fa-check"></i>Rehabilitation</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="risk-stratification.html"><a href="risk-stratification.html"><i class="fa fa-check"></i>Risk Stratification</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html"><i class="fa fa-check"></i>Treatment Considerations</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#hydroxychloroquinechloroquine"><i class="fa fa-check"></i>Hydroxychloroquine/Chloroquine</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#mechanism"><i class="fa fa-check"></i>Mechanism</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#evidence"><i class="fa fa-check"></i>Evidence</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#recommendations-4"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#remdesivir"><i class="fa fa-check"></i>Remdesivir</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#mechanism-1"><i class="fa fa-check"></i>Mechanism</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#evidence-1"><i class="fa fa-check"></i>Evidence</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#recommendations-5"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#lopinavir-ritonavir"><i class="fa fa-check"></i>Lopinavir-Ritonavir</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#mechanism-2"><i class="fa fa-check"></i>Mechanism</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#evidence-2"><i class="fa fa-check"></i>Evidence</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#recommendations-6"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#il-6-inhibitorsimmunomodulators"><i class="fa fa-check"></i>IL-6 inhibitors/Immunomodulators</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#mechanism-3"><i class="fa fa-check"></i>Mechanism</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#convalescent-serumplasma"><i class="fa fa-check"></i>Convalescent Serum/Plasma</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#mechanism-4"><i class="fa fa-check"></i>Mechanism</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#evidence-3"><i class="fa fa-check"></i>Evidence</a></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#recommendations-7"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#antibiotics"><i class="fa fa-check"></i>Antibiotics</a><ul>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#recommendations-8"><i class="fa fa-check"></i>Recommendations</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="treatment-considerations-4.html"><a href="treatment-considerations-4.html#post-exposure-prophylaxis"><i class="fa fa-check"></i>Post-Exposure Prophylaxis</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html"><i class="fa fa-check"></i>Cardiovascular Medication Considerations</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#acearbarni"><i class="fa fa-check"></i>ACE/ARB/ARNI</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#pathophysiology-2"><i class="fa fa-check"></i>Pathophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#potential-harms"><i class="fa fa-check"></i>Potential Harms</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#potential-benefits"><i class="fa fa-check"></i>Potential Benefits</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#recommendation"><i class="fa fa-check"></i>Recommendation</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#nsaids"><i class="fa fa-check"></i>NSAIDs</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#pathophysiology-3"><i class="fa fa-check"></i>Pathophysiology</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#potential-harms-1"><i class="fa fa-check"></i>Potential Harms</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#potential-benefits-1"><i class="fa fa-check"></i>Potential Benefits</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#recommendation-1"><i class="fa fa-check"></i>Recommendation</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#chloroquinehydroxychloroquine"><i class="fa fa-check"></i>Chloroquine/Hydroxychloroquine</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#toxicity"><i class="fa fa-check"></i>Toxicity</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#monitoring"><i class="fa fa-check"></i>Monitoring</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#azithromycin"><i class="fa fa-check"></i>Azithromycin</a><ul>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#toxicity-1"><i class="fa fa-check"></i>Toxicity</a></li>
<li class="chapter" data-level="" data-path="cardiovascular-medication-considerations.html"><a href="cardiovascular-medication-considerations.html#monitoring-1"><i class="fa fa-check"></i>Monitoring</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="" data-path="penn-resources.html"><a href="penn-resources.html"><i class="fa fa-check"></i>Penn Resources</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html"><i class="fa fa-check"></i>Major Cardiovascular Society Resources</a><ul>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#american-college-of-cardiology-acc"><i class="fa fa-check"></i>American College of Cardiology (ACC)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#american-heart-association-aha"><i class="fa fa-check"></i>American Heart Association (AHA)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#european-society-of-cardiology-esc"><i class="fa fa-check"></i>European Society of Cardiology (ESC)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#society-for-cardiovascular-angiography-and-interventions-scai"><i class="fa fa-check"></i>Society for Cardiovascular Angiography and Interventions (SCAI)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#heart-rhythm-society-hrs"><i class="fa fa-check"></i>Heart Rhythm Society (HRS)</a></li>
<li class="chapter" data-level="" data-path="major-cardiovascular-society-resources.html"><a href="major-cardiovascular-society-resources.html#american-society-of-echocardiography-ase"><i class="fa fa-check"></i>American Society of Echocardiography (ASE)</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="clinical-trials.html"><a href="clinical-trials.html"><i class="fa fa-check"></i>Clinical Trials</a></li>
<li class="chapter" data-level="" data-path="limited-resource-allocation.html"><a href="limited-resource-allocation.html"><i class="fa fa-check"></i>Limited Resource Allocation</a></li>
<li class="chapter" data-level="" data-path="journal-resources.html"><a href="journal-resources.html"><i class="fa fa-check"></i>Journal Resources</a></li>
<li class="chapter" data-level="" data-path="social-media-resources.html"><a href="social-media-resources.html"><i class="fa fa-check"></i>Social Media Resources</a></li>
<li class="chapter" data-level="" data-path="miscellaneous-notesresources.html"><a href="miscellaneous-notesresources.html"><i class="fa fa-check"></i>Miscellaneous Notes/Resources</a></li>
<li class="chapter" data-level="" data-path="recent-updates.html"><a href="recent-updates.html"><i class="fa fa-check"></i>Recent Updates</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown">
Published with Bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">COVID-19 Resources for Penn Cardiologists</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="cardiovascular-manifestations-of-covid-19" class="section level1">
<h1>Cardiovascular Manifestations of COVID-19</h1>
<div id="acute-cardiac-injury" class="section level2">
<h2>Acute Cardiac Injury</h2>
<div id="definition" class="section level3">
<h3>Definition</h3>
<p>Serum levels of <a href="cardiovascular-testing-considerations.html#cardiac-biomarkers">cardiac biomarkers</a> (eg, high-sensitivity cardiac troponin I) above the 99th percentile upper reference limit, or new electrocardiographic and echocardiographic abnormalities (<a href="https://pubmed.ncbi.nlm.nih.gov/31986264/">Huang, et al., Lancet, 2020</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</p>
</div>
<div id="pathophysiology" class="section level3">
<h3>Pathophysiology</h3>
<p>May occur directly as consequence of virus-associated <a href="cardiovascular-manifestations-of-covid-19.html#acute-coronary-syndrome">Acute Coronary Syndrome</a>, <a href="cardiovascular-manifestations-of-covid-19.html#arrhythmia">Arrhythmia</a>, <a href="cardiovascular-manifestations-of-covid-19.html#myopericarditis">Myo/Pericarditis</a>, or <a href="cardiovascular-manifestations-of-covid-19.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release">Cytokine Release</a>, or indirectly associated with the combination of acute illness and underlying hypertension, coronary artery disease, heart failure, structural heart disease, chronic kidney disease, or diabetes (<a href="https://pubmed.ncbi.nlm.nih.gov/32219362">Bonow, et al. JAMA Cardiology 2020</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/30153967">Thygesen, et al., JACC, 2018</a>)</p>
</div>
<div id="diagnostics" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li><a href="cardiovascular-testing-considerations.html#cardiac-biomarkers">Cardiac troponin, NT-proBNP</a><br />
</li>
<li><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry">ECG</a><br />
</li>
<li>Consider <a href="cardiovascular-testing-considerations.html#echocardiography">limited echocardiogram</a><br />
</li>
<li>Consider measurement of inflammatory markers to evaluate hyperinflammation (Ferritin, IL-6, LDH, D-dimer)</li>
</ul>
</div>
<div id="incidence" class="section level3">
<h3>Incidence</h3>
<ul>
<li>12% overall, 31% ICU, 4% non-ICU (among 41 patients total) (<a href="https://pubmed.ncbi.nlm.nih.gov/31986264/">Huang, et al., Lancet, 2020</a>)</li>
<li>17% overall (among 191 patients total) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
<li>19.7% overall (among 416 patients overall) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>27.8% (n = 52) (among 187 patients overall) (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
</ul>
</div>
<div id="prognostic-implications" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Associated with increased utilization of noninvasive ventilation (38 [46.3%] vs 13 [3.9%]; P &lt; .001) and invasive mechanical ventilation (18 [22.0%] vs 14 [4.2%]; P &lt; .001) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>Associated with increased mortality
<ul>
<li>Occured in 59% of non-survivors (N = 32) vs. 1% of survivors (N = 1) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
<li>Adjusted HR 4.26 [95% CI, 1.92-9.49] p &lt; 0.001) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>Mortality 59.6% (n = 31) in individuals with ↑TnT vs. 8.9% (n = 12) with normal TnT; p &lt; 0.001 (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
<li>Possible interaction between underlying cardiovascular disease (CVD) and myocardial injury
<ul>
<li>Mortality 7.62% (8 of 105) among patients without CVD + normal TnT, 13.33% (4 of 30) for underlying CVD + normal TnT levels, 37.50% (6 of 16) for those without underlying CVD + ↑TnT levels, and 69.44% (25 of 36) for underlying CVD + ↑TnT (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="treatment-considerations" class="section level3">
<h3>Treatment Considerations</h3>
<ul>
<li>Supportive care</li>
<li>If associated with concomittant <a href="cardiovascular-manifestations-of-covid-19.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release">hyperinflammation/cytokine storm/secondary HLH</a>, consider anti-IL6 or anti-IL1 therapy</li>
</ul>
</div>
</div>
<div id="acute-coronary-syndrome" class="section level2">
<h2>Acute Coronary Syndrome</h2>
<div id="definition-1" class="section level3">
<h3>Definition</h3>
<ul>
<li>Acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia <a href="https://pubmed.ncbi.nlm.nih.gov/30153967">(Thygesen, et al., JACC, 2018)</a></li>
<li>Must be differentiated from other causes of <a href="cardiovascular-manifestations-of-covid-19.html#acute-cardiac-injury">Acute Cardiac Injury</a></li>
</ul>
</div>
<div id="pathophysiology-1" class="section level3">
<h3>Pathophysiology</h3>
<ul>
<li>Myocardial ischemia as a consequence of atherothrombotic coronary artery disease (eg. plaque disruption; Type I MI), mismatch between oxygen supply and demand (Type II MI), in association with cardiac death (eg. Type III MI), related to percutaneous coronary intervention (Type IV MI), or associated with coronary artery bypass grafting (Type V MI)</li>
</ul>
</div>
<div id="incidence-1" class="section level3">
<h3>Incidence</h3>
<ul>
<li>As of 3/2020, case reports of acute coronary syndromes (ACS) (Type 1 MI) in the setting of COVID-19 have yet to be published (<a href="https://pubmed.ncbi.nlm.nih.gov/32201335">Driggin, et al., JACC, 2020</a>)</li>
<li>Severe respiratory has been identified as a risk factor for acute myocardial infarction
<ul>
<li>Incidence ratio [IR] 6.1, 95% CI 3.9-9.5 following influenza; IR 2.8, 95% CI 1.2–6.2 following non-influenza viral illness (<a href="https://pubmed.ncbi.nlm.nih.gov/29365305/">Kwong, et al., NEJM, 2018</a>)</li>
</ul></li>
</ul>
</div>
<div id="diagnostics-1" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li><a href="cardiovascular-testing-considerations.html#cardiac-biomarkers">Cardiac troponin, NT-proBNP</a>, lipid screen, A1c</li>
<li><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry">ECG</a></li>
<li>Consider <a href="cardiovascular-testing-considerations.html#echocardiography">limited echocardiogram</a></li>
</ul>
</div>
<div id="treatment-considerations-scai-guidelines" class="section level3">
<h3>Treatment Considerations (SCAI Guidelines)</h3>
<p>See <a href="https://pubmed.ncbi.nlm.nih.gov/32212409">Szerlip, et al., Catheterization and Cardiovascular Interventions, 2020</a>, summarized below:</p>
<div id="stemi" class="section level4">
<h4>STEMI</h4>
<ul>
<li>Primary PCI for <strong><em>high risk</em></strong> patients (anterior location, hypotension, elevated Killip class, cardiogenic shock, life-threatening, delayed presentation &gt;12 hours)</li>
<li>Consider fibrinolysis for <strong><em>low risk</em></strong> patients without contraindications (intracranial hemorrhage, prior stroke, recent trauma/surgery, intracranial malignancy/arteriovenous malformation/aneurysm, active bleeding, uncontrolled hypertension); otherwise consider primary PCI or medical management</li>
</ul>
</div>
<div id="nstemi" class="section level4">
<h4>NSTEMI</h4>
<ul>
<li>Early angiography (&lt;2 hours) for <strong><em>very high risk</em></strong> patients (refractory chest pain, heart failure, cardiogenic shock, life-threatening arrhythmia)</li>
<li>Conservative management for <strong><em>non-very high risk</em></strong> patients with antiplatelet therapy, anticoagulation (48 hours), high-intensity statin, beta-blocker, ACE-inhibitor (if indicated)</li>
</ul>
</div>
</div>
</div>
<div id="arrhythmia" class="section level2">
<h2>Arrhythmia</h2>
<div id="incidence-2" class="section level3">
<h3>Incidence</h3>
<ul>
<li>16.7% overall (n = 23/138); 44% of patients transferred to ICU (n = 16/36) (<a href="https://pubmed.ncbi.nlm.nih.gov/32031570/">Wang, et al., JAMA, 2020</a>)</li>
<li>VT/VF in 5.9% (n = 11/187) (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)
<ul>
<li>Elevated troponin levels at baseline were associated with increased in-hospital VT/VF (17.3% vs. 2%, P&lt;0.001)</li>
</ul></li>
<li>Palpitations in 7.2% (n = 10) (<a href="https://pubmed.ncbi.nlm.nih.gov/32044814">Liu, et al., Chinese Medical Journal, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-2" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>BMP, magnesium, TSH</li>
<li><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry">ECG</a></li>
<li><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry">Telemetry</a></li>
<li>Consider <a href="cardiovascular-testing-considerations.html#echocardiography">limited echocardiogram</a></li>
</ul>
</div>
<div id="treatment-considerations-1" class="section level3">
<h3>Treatment Considerations</h3>
<div id="atrial-fibrillationflutter" class="section level4">
<h4>Atrial Fibrillation/Flutter</h4>
<ul>
<li>No hypotension/shock: Beta blockade and/or calcium-channel blockade</li>
<li>Hypotension/shock: Consider amiodarone infusion</li>
</ul>
</div>
<div id="ventricular-tachycardia" class="section level4">
<h4>Ventricular Tachycardia</h4>
<ul>
<li>Pulseless/Unstable: ACLS, defibrillation/cardioversion</li>
<li>Stable: Consider amiodarone or lidocaine infusion</li>
</ul>
</div>
<div id="bradyarrhythmia" class="section level4">
<h4>Bradyarrhythmia</h4>
<ul>
<li>Consider epinephrine, dopamine, isoproteronol, temporary pacemaker</li>
</ul>
</div>
</div>
</div>
<div id="myopericarditis" class="section level2">
<h2>Myo/Pericarditis</h2>
<div id="incidence-3" class="section level3">
<h3>Incidence</h3>
<ul>
<li>Myocarditis and pericarditis may be sources of acute cardiac injury based on case reports, overall incidence unclear (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32125452">Ruan et al, Intensive Care Med, 2020</a>; <a href="http://dx.doi.org/10.20944/preprints202003.0180.v1">Zeng et al, Preprints, 2020</a>; <a href="http://www.ncbi.nlm.nih.gov/pubmed/32176300">Hu et al, Eur Heart J, 2020</a>; <a href="https://pubmed.ncbi.nlm.nih.gov/32219357">Inciardi, et al., JAMA Cardiology 2020</a>)</li>
<li>No clear evidence of myocarditis on limited cardiac biopsy <a href="https://pubmed.ncbi.nlm.nih.gov/32085846">(Xu, et al., Lancet Respir Med, 2020)</a></li>
</ul>
</div>
<div id="clinical-presentation" class="section level3">
<h3>Clinical Presentation</h3>
<p>Myo/Pericarditis may present with a broad spectrum and severity of symptoms including chest pain, palpitations, tachycardia/bradycardia, elevated cardiac biomarkers, or acute-onset heart failure with cardiogenic shock.</p>
</div>
<div id="diagnostics-3" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li><a href="cardiovascular-testing-considerations.html#cardiac-biomarkers">Cardiac troponin, NT-proBNP</a></li>
<li>Physical exam may demonstrate pericardial friction rub, signs of heart failure (S3, elevated jugular venous pressure, edema)</li>
<li><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry">ECG</a> - case reports of pseudo-STEMI manifestations
<ul>
<li>Diffuse ST-segment elevation with PR-segment depression</li>
</ul></li>
<li>Consider <a href="cardiovascular-testing-considerations.html#echocardiography">limited echocardiogram</a><br />
</li>
<li>Unclear role of endomyocardial biopsy (to evaluate direct viral effects) and/or cardiac MRI/CT (to evaluate for myocardial inflammation and the presence of underlying coronary artery disease)</li>
</ul>
</div>
<div id="management" class="section level3">
<h3>Management</h3>
<ul>
<li>Supportive treatment
<ul>
<li><strong>Acute Heart Failure:</strong> avoid medications with negative chronotropic/inotropic effects (eg. beta-blockers, calcium-channel blockers) if concerned for new heart failure as cardiac output may be dependent on tachycardia; avoid NSAIDs which may lead to fluid retention and myocardial injury. See <a href="cardiovascular-manifestations-of-covid-19.html#cardiomyopathyheart-failurecardiogenic-shock">Cardiomyopathy/Heart Failure/Cardiogenic Shock</a>.</li>
<li><strong>Arrhythmia:</strong> see <a href="cardiovascular-manifestations-of-covid-19.html#arrhythmia">Arrhythmia</a></li>
<li><strong>Pericarditis without myocardial involvement:</strong> consider colchicine, NSAIDs</li>
</ul></li>
<li>Consider anti-inflammatory/immunomodulators if concomittant <a href="cardiovascular-manifestations-of-covid-19.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release">Cytokine Release</a>; Anecdotal/case reports describe treatment with steroids and IVIG</li>
</ul>
</div>
</div>
<div id="thromboembolic-diseasecoagulopathy" class="section level2">
<h2>Thromboembolic Disease/Coagulopathy</h2>
<div id="incidence-4" class="section level3">
<h3>Incidence</h3>
<ul>
<li>Mild thrombocytopenia (platelets 100-150) in 20% (n = 13) (<a href="https://pubmed.ncbi.nlm.nih.gov/32129508">Fan, et al., American Journal of Hematology, 2020</a>)</li>
<li>Coaguloapthy in 34.1% (n = 42) (<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2020.1017">Guo, et al., JAMA Cardiology, 2020</a>)</li>
<li>Coagulopathy (defined as 3-second extension of PT or a 5-second extension of aPTT) in 19% (n = 37) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-4" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li><a href="cardiovascular-testing-considerations.html#coagulation-biomarkers">CBC with differential, D-dimer, PT/INR, aPTT, fibrinogen, peripheral smear</a></li>
</ul>
</div>
<div id="prognostic-implications-1" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Elevated D-dimer levels (&gt;1g/L) associated with in-hospital death (adjusted OR 18.4 95% CI 2.6-128.6, p=0.003) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)<br />
</li>
<li>Coagulopathy present in 50% (n = 27) of non-survivors vs. 7% (n = 10) in survivors (p &lt;0.001) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)<br />
</li>
<li>Disseminated intravascular coagulation present in 71.4% (n = 15) of non-survivors vs. 0.6% (n = 1) in survivors (<a href="https://pubmed.ncbi.nlm.nih.gov/32073213">Tang, et al., Journal of Thrombosis and Haemostasis, 2020</a>)</li>
</ul>
</div>
<div id="treatment-considerations-2" class="section level3">
<h3>Treatment Considerations</h3>
<ul>
<li>VTE prophylaxis in all hospitalized patients with COVID-19</li>
<li>A retrospective study in China of 449 consecutive cases of severe COVID-19 showed benefit of LMWH in patients with high D-Dimer, PT times, and Sepsis Induced Coagulopathy score &gt; 4 (<a href="https://pubmed.ncbi.nlm.nih.gov/32220112">Tang, et al., Journal of Thrombosis and Haemostasis, 2020</a>)</li>
<li>Current ISTH proposed guidelines suggest prophylactic anticoagulation with LMWH (<a href="https://doi.org/10.1111/jth.14810">Thachil et al, Journal of Thrombosis and Haemostasis, 2020</a>)</li>
</ul>
</div>
</div>
<div id="secondary-hemophagocytic-lymphohistiocytosiscytokine-release" class="section level2">
<h2>Secondary Hemophagocytic Lymphohistiocytosis/Cytokine Release</h2>
<div id="definition-2" class="section level3">
<h3>Definition</h3>
<p>Hyperinflammatory syndrome characterised by macrophage activation and fulminant hypercytokinemia, associated with multiorgan failure and shock.</p>
</div>
<div id="clinical-presentation-1" class="section level3">
<h3>Clinical Presentation</h3>
<ul>
<li>Fever, splenomegaly, cytopenias, and hyperferritinemia, with progression to ARDS in 54% (<a href="https://pubmed.ncbi.nlm.nih.gov/26836913">Seguin, et al., Chest, 2016</a>)</li>
<li>May be associated with <a href="cardiovascular-manifestations-of-covid-19.html#acute-cardiac-injury">Acute Cardiac Injury</a> (<a href="https://pubmed.ncbi.nlm.nih.gov/32139904">Zheng, et al., Nat Rev Cardiol, 2020</a>)</li>
</ul>
</div>
<div id="incidence-5" class="section level3">
<h3>Incidence</h3>
<ul>
<li>Unclear incidence/prevalence in COVID-19, although a similar pattern of dysregulated immune response has been reported (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32192578">Mehta et al, Lancet, 2020</a>)</li>
<li>Similar response identified in SARS-CoV-1 and MERS infections (<a href="http://www.ncbi.nlm.nih.gov/pubmed/27709848">Kim et al, J Korean Med Sci, 2016</a>)</li>
<li>Occurs in 3.7-4.3% of patients with sepsis (<a href="https://pubmed.ncbi.nlm.nih.gov/30766533">Karakike, et al., Frontiers in Immunology, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-5" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li><a href="cardiovascular-testing-considerations.html#coagulation-biomarkers">CBC with differential, PT/INR, aPTT, fibrinogen, D-dimer</a>, hepatic function panel, triglycerides, <a href="cardiovascular-testing-considerations.html#inflammatory-biomarkers">inflammatory markers (ESR/CRP/ferritin/LDH); consider NK-function, soluble IL-2 receptor in discussion with hematology/oncology</a></li>
<li>Calculate H-score (<a href="https://www.mdcalc.com/hscore-reactive-hemophagocytic-syndrome">MDcalc</a>)</li>
</ul>
</div>
<div id="prognostic-implications-2" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Associated with rapid progression to ARDS, shock, and multiorgan failure (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32007143">Chen et al, Lancet, 2020</a>)</li>
</ul>
</div>
<div id="treatment-considerations-3" class="section level3">
<h3>Treatment Considerations</h3>
<ul>
<li>Care typically supportive</li>
<li>Consideration of IVIG, steroids (may be associated with worsened lung injury), enrollment in clinical trial (or off-label use) of cytokine blockade (<a href="treatment-considerations-4.html#il-6-inhibitorsimmunomodulators">IL-6 antagonists</a> [eg. tocilizumab, sarilumab, siltuximab] or IL-1 antagonists [eg. anakinra])</li>
</ul>
</div>
</div>
<div id="cardiomyopathyheart-failurecardiogenic-shock" class="section level2">
<h2>Cardiomyopathy/Heart Failure/Cardiogenic Shock</h2>
<div id="incidence-6" class="section level3">
<h3>Incidence</h3>
<ul>
<li>23% overall (n = 44) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
<li>33% (n = 7) of ICU patients in Washington State (<a href="http://www.ncbi.nlm.nih.gov/pubmed/32191259">Arentz et al., JAMA, 2020</a>)</li>
</ul>
</div>
<div id="diagnostics-6" class="section level3">
<h3>Diagnostics</h3>
<ul>
<li>Physical Exam: ↑JVP/CVP, edema, rales/crackles
<ul>
<li>Pulse pressure &lt; 25% of SBP correlates highly with cardiac index &lt; 2.2 (sensitivity 91%, specificity 83%) (<a href="http://www.ncbi.nlm.nih.gov/pubmed/2913385">Stevenson and Perloff, JAMA, 1989</a>)</li>
</ul></li>
<li>Labs: <a href="cardiovascular-testing-considerations.html#cardiac-biomarkers">Cardiac troponin, NT-proBNP</a>, lactate, central/mixed venous oxygen saturation (ScVO2) if available; consider evaluation of <a href="cardiovascular-manifestations-of-covid-19.html#secondary-hemophagocytic-lymphohistiocytosiscytokine-release">Cytokine Release</a> with <a href="cardiovascular-testing-considerations.html#inflammatory-biomarkers">Inflammatory Biomarkers</a></li>
<li><a href="cardiovascular-testing-considerations.html#electrocardiographytelemetry">ECG</a></li>
<li>Chest x-ray</li>
<li>Consider <a href="cardiovascular-testing-considerations.html#echocardiography">limited echocardiogram</a></li>
</ul>
</div>
<div id="prognostic-implications-3" class="section level3">
<h3>Prognostic Implications</h3>
<ul>
<li>Chronic heart failure associated with increased risk of acute cardiac injury (14.6% vs. 1.5%) (<a href="https://pubmed.ncbi.nlm.nih.gov/32211816">Shi, et al., JAMA Cardiology, 2020</a>)</li>
<li>Associated with increased risk of mortality, more common in non-survivors (52%, n = 28) vs. survivors (12%, n = 16) (<a href="https://pubmed.ncbi.nlm.nih.gov/32171076/">Zhou, et al., Lancet, 2020</a>)</li>
</ul>
</div>
<div id="management-1" class="section level3">
<h3>Management</h3>
<div id="stablechronic" class="section level4">
<h4>Stable/Chronic</h4>
<ul>
<li>Goal-directed medical therapy with beta-blockade, ACE/ARB/ARNI, mineralocorticoid receptor antagonist</li>
<li><a href="https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang">ESC</a> and <a href="https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp">HFSA/ACC/AHA</a> recommend continuation of ACE/ARB/ARNI. See <a href="cardiovascular-medication-considerations.html#cardiovascular-medication-considerations">Cardiovascular Medication Considerations</a></li>
</ul>
</div>
<div id="unstablecardiogenic-shock" class="section level4">
<h4>Unstable/Cardiogenic Shock</h4>
<ul>
<li>Consider invasive hemodynamic monitoring with arterial and central venous catheters</li>
<li>Goals: MAPs 65-75, CVP 6-14, PCWP 12-18, PAD 20-25, SVR 800-1000, SCvO2 &gt; 60%, CI &gt; 2.2 (Note: Achieving MAP goal is first priority, then optimize other parameters)</li>
<li>Ensure negative inotropes such as beta blockers, calcium channel blockers and antihypertensives are discontinued.</li>
<li>Titration of norepinephrine infusion for goal MAP 65-75</li>
<li>Initiate diuretic therapy for CVP &gt; 14, PCWP &gt;18, PAD &gt; 25</li>
<li>Consider inotropic support (eg. dobutamine or epinephrine infusions)</li>
</ul>
</div>
</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="index.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="cardiovascular-testing-considerations.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": true,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"all": ["facebook", "twitter"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
